Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "The Primary Endpoint Analysis of the Phase II SCARLET Study - Sotorasib + Carboplatin-Pemetrexed in Pts With Advanced Non-Squamous NSCLC With KRAS G12C Mutation"
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Hiroaki Akamatsu
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Hiroaki Akamatsu
Login to view comments.
Click here to Login